Biotech Cost Ceiling II

The New York Times had an article about a biotech cost ceiling looking at treatments for Psoriasis.  I wasn't sure it was the best example but more news supports the articles principle argument:

The new Pharmacor report Crohn's Disease finds that third-party payers
in both the United States and Europe impose significant limitations on the
use of biologics to treat the disease. One of the limitations in most of
the major pharmaceutical markets is that patients must fail to respond to
at least two conventional therapies, such as corticosteroids and
immunosuppressants, before receiving treatment with a biological agent. As
a result, only a small percentage of Crohn's disease patients will be
treated with biologics during the 2005-2015 forecast period.